December 7, 2007

Solid facts to understanding shock

Discovering the structure of a key protein in human cells may lead to treatment for asthma and shock

Figure 1: The crystal structure of the trimer of the enzyme, leukotriene C4 synthase, binding a small, natural compound, points to how drug molecules could be designed to bind in a similar fashion.

The structure of a complex, human protein that has been uncovered by collaborators from Japan and the US could lead to new treatments for chronic inflammation illnesses such as asthma.

Good anti-inflammatory drugs are essential for the treatment of chronic conditions such as asthma and anaphylaxis, in which the lungs are severely restricted—sometimes fatally. According to the World Health Organization, it is estimated that as many as 300 million people worldwide suffer from asthma, so effective treatments are imperative.

The causes of chronic inflammation in humans are complex. The main compound known to trigger asthmatic symptoms is leukotriene C4, which is synthesized in the body by an enzyme known as leukotriene C4 synthase (LTC4S). This enzyme is of great interest to scientists, because if drugs can be designed to regulate the activity of LTC4S in the body and control the amounts of inflammation inducing leukotriene C4, then a cure for asthma could be possible.

Now, a research team led by Hideo Ago at the RIKEN SPring-8 Center in Harima, in collaboration with K. Frank Austen at the Harvard Medical School and Division of Rheumatology, Immunology, and Allergy in Massachusetts, has solved the crystal structure of LTC4S which shows the enzyme as a trimer (Fig. 1). Their work provides a breakthrough to scientists and opens the door to structure-based design of possible drug compounds.

From the crystal structure, published in the journal Nature1, Ago and colleagues can now also look more closely at the biological function of the enzyme and its mechanism in cells. This significant achievement was not without challenges. The team also had to develop a way of producing the active human enzyme in sufficient quantities to form crystals for study. This was done using a recombinant technique—a procedure that allowed large quantities of LTC4S to be produced using fission yeast instead of human cells.

The research program to date has involved the work of eight scientists over four years from both institutes. Ago explains that the next step in this research will be to use this new crystal structure to screen, using computers, potential drug candidates for effective inhibitors of the enzyme. This approach may lead to better therapeutic drugs. The group will also study similar biological systems that produce active compounds.

Ago is very optimistic about the future. “In the new project, the technical know-how established through the study on LTC4S will be a great help,” he says.


  1. Ago, H., Kanaoka, Y., Irikura, D., Lam, B.K., Shimamura, T., Austen, K.F. & Miyano, M. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 448, 609–612 (2007). |  | (Link)